Alzheimer’s disease in Down syndrome similar to the autosomal dominant form | Health

WEDNESDAY, May 25, 2022 (HealthDay News) — Variability in age at onset of Alzheimer’s disease symptoms with Down syndrome is similar to autosomal dominant Alzheimer’s disease, while mortality data are consistent with fully penetrating Alzheimer’s disease, according to a study published online May 23 at Open JAMA Network.

Maria Florencia Iulita, Ph.D., of the Universitat Autònoma de Barcelona in Spain, and her colleagues assessed whether the variability in the onset of Alzheimer’s disease symptoms in Down syndrome is similar to that in Down syndrome. Dominant Alzheimer’s disease and its association with mortality. In addition to a literature search and meta-analysis, the analysis included mortality data from US death certificates (77,347 case records from 1968 to 2019) and 889 people from the Down Alzheimer Barcelona Neuroimaging Initiative.

The researchers found that the estimated age at onset was 53.8 years and the estimated age at death was 58.4 years for Alzheimer’s disease dementia in Down syndrome . Ages of onset were comparable to those reported in autosomal dominant Alzheimer’s disease. An increase in Down syndrome life expectancy (median, 1 year in 1968 to 57 years in 2019) was noted using US mortality data, but with clear ceiling effects in the highest percentiles age at death in recent decades. These mortality data met projected limits with fully penetrating Alzheimer’s disease in up to 80% of deaths (corresponding to the highest percentiles). In 2019, racial disparities persisted and were more pronounced in the lower percentiles (10th percentile: black individuals, 1 year old; white individuals, 30 years old) than in the upper percentiles (90th percentile: black individuals, 64 years old; white individuals, 66 year ).

“The lifespan of people with Down syndrome will not increase until modifying treatments for Alzheimer’s disease become available,” the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Summary/Full text

Recent stories you might have missed

Comments are closed.